RT Journal Article
SR Electronic
T1 Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.05.15.23289680
DO 10.1101/2023.05.15.23289680
A1 Middha, Pooja
A1 Thummalapalli, Rohit
A1 Betti, Michael J.
A1 Yao, Lydia
A1 Quandt, Zoe
A1 Balaratnam, Karmugi
A1 Bejan, Cosmin A.
A1 Cardenas, Eduardo
A1 Falcon, Christina J.
A1 Faleck, David M.
A1 Princess Margaret Lung Group
A1 Gubens, Matthew A.
A1 Huntsman, Scott
A1 Johnson, Douglas B.
A1 Kachuri, Linda
A1 Khan, Khaleeq
A1 Li, Min
A1 Lovly, Christine M.
A1 Murray, Megan H.
A1 Patel, Devalben
A1 Werking, Kristin
A1 Xu, Yaomin
A1 Zhan, Luna Jia
A1 Balko, Justin M.
A1 Liu, Geoffrey
A1 Aldrich, Melinda C.
A1 Schoenfeld, Adam J.
A1 Ziv, Elad
YR 2023
UL http://medrxiv.org/content/early/2023/09/13/2023.05.15.23289680.abstract
AB Immune checkpoint inhibitors (ICIs) are a remarkable advancement in cancer therapeutics; however, a substantial proportion of patients develop severe immune-related adverse events (irAEs). Understanding and predicting irAEs is a key to advancing precision immuno-oncology. Immune checkpoint inhibitor-mediated colitis (IMC) is a significant complication from ICI and can have life-threatening consequences. Based on clinical presentation, IMC mimics inflammatory bowel disease, however the link is poorly understood. We hypothesized that genetic susceptibility to Crohn’s disease (CD) and ulcerative colitis (UC) may predispose to IMC. We developed and validated polygenic risk scores for CD (PRSCD) and UC (PRSUC) in cancer-free individuals and assessed the role of each of these PRSs on IMC in a cohort of 1,316 patients with non-small cell lung cancer who received ICIs. Prevalence of all-grade IMC in our cohort was 4% (55 cases), and for severe IMC, 2.5% (32 cases). The PRSUC predicted the development of all-grade IMC (HR=1.34 per standard deviation [SD], 95% CI=1.02-1.76, P=0.04) and severe IMC (HR=1.62 per SD, 95% CI=1.12-2.35, P=0.01). PRSCD was not associated with IMC or severe IMC. The association between PRSUC and IMC (all-grade and severe) was consistent in an independent pan-cancer cohort of patients treated with ICIs. Furthermore, PRSUC predicted severe IMC among patients treated with combination ICIs (OR = 2.20 per SD, 95% CI = 1.07-4.53, P=0.03). This is the first study to demonstrate the potential clinical utility of a PRS for ulcerative colitis in identifying patients receiving ICI at high risk of developing IMC, where risk reduction and close monitoring strategies could help improve overall patient outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Institutes of Health R01CA227466 and K24CA169004 to E.Ziv. C.M.Lovly was supported in part by NIH NCI UG1CA233259, P01CA129243, and P30CA068485. R.Thummalapalli was supported by T32-CA009207. The Lusi Wong Fund, Posluns Fund, Alan Brown Chair in Molecular Genomics, Princess Margaret Cancer Foundation were awarded to G. Liu for this work. M.C. Aldrich was supported in part by R01CA227466, U01CA253560, R01CA251758 and the Vanderbilt Institute for Clinical and Translational Research (UL1TR002243). Z. Quandt was supported by the American Diabetes Association Grant (1 19 PDF 131). A.J.Schoenfeld, D.Faleck were supported by the Memorial Sloan Kettering Cancer Center Support Grant/Core (P30CA008748), the Druckenmiller Center for Lung Cancer Research at Memorial Sloan Kettering Cancer Center. The samples and/or dataset(s) used for the analyses described were obtained from Vanderbilt University Medical Center BioVU which is supported by numerous sources: institutional funding, private agencies, and federal grants. These include the NIH funded Shared Instrumentation Grant S10OD017985 and S10RR025141; and CTSA grants UL1TR002243, UL1TR000445, and UL1RR024975. Genomic data are also supported by investigator-led projects that include U01HG004798, R01NS032830, RC2GM092618, P50GM115305, U01HG006378, U19HL065962, R01HD074711; and additional funding sources listed at https://victr.vumc.org/biovu-funding/Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board approvals were obtained at each site (University of California San Francisco, Vanderbilt University Medical Center, Memorial Sloan Kettering Cancer Center, Princess Margaret Cancer Center) individually and written informed consent was acquired from all study participants prior to inclusion in the study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study will be available by dbGAP. The dbGAP submission is pending for GeRI cohort data and will be under control access.